Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• The mechanistic target of rapamycin (mTOR) pathway regulates cell growth and is a target for cancer therapy.
• mTOR also plays a critical role in T-cell function, including anti-tumor immune responses.
• Rapamycin, an mTOR inhibitor, has shown limited clinical efficacy in cancer treatment.

Purpose of the Study:

• To investigate the impact of rapamycin on T-cell-mediated anti-tumor immune responses in the context of cancer vaccine therapy.
• To evaluate the effect of rapamycin on the efficacy of a human papilloma virus E7 peptide vaccine (CyaA-E7) in a cervical cancer mouse model.

Main Methods:

• Utilized a TC-1 mouse model of cervical cancer.
• Administered CyaA-E7 vaccine with or without rapamycin.
• Analyzed T-cell infiltration (CD8+ T cells, regulatory T cells), myeloid-derived suppressor cells, and vaccine-induced cytotoxic T-cell responses.

Main Results:

• Rapamycin administration abolished CD8+ T-cell recruitment into tumors.
• Rapamycin impaired the vaccine's ability to reduce regulatory T cells and myeloid-derived suppressor cells.
• Rapamycin completely abolished vaccine-induced cytotoxic T-cell responses and therapeutic efficacy.

Conclusions:

• mTOR inhibition by rapamycin abrogates T-cell-mediated anti-tumor immune responses.
• Rapamycin is detrimental to the therapeutic efficacy of cancer vaccines.
• Targeting mTOR may negatively impact anti-tumor immunity, necessitating careful consideration in cancer therapy development.